Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals ...

Pfizer shares currently trade at approximately $23, down 13% year-to-date and significantly below their 2021 peak of around $60. The company experienced extraordinary growth during the COVID-19 ...

Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

Pfizer will end research into treatments for Alzheimer's and Parkinson's disease, resulting in the elimination of 300 positions at the company's Massachusetts facilities in Andover and Cambridge ...